BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33393006)

  • 1. Romidepsin hepatocellular carcinoma suppression in mice is associated with deregulated gene expression of bone morphogenetic protein and Notch signaling pathway components.
    Afaloniati H; Poutahidis T; Giakoustidis A; Gargavanis A; Giakoustidis D; Angelopoulou K
    Mol Biol Rep; 2021 Jan; 48(1):551-562. PubMed ID: 33393006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bile acids promote diethylnitrosamine-induced hepatocellular carcinoma via increased inflammatory signaling.
    Sun L; Beggs K; Borude P; Edwards G; Bhushan B; Walesky C; Roy N; Manley MW; Gunewardena S; O'Neil M; Li H; Apte U
    Am J Physiol Gastrointest Liver Physiol; 2016 Jul; 311(1):G91-G104. PubMed ID: 27151938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutive Notch2 signaling induces hepatic tumors in mice.
    Dill MT; Tornillo L; Fritzius T; Terracciano L; Semela D; Bettler B; Heim MH; Tchorz JS
    Hepatology; 2013 Apr; 57(4):1607-19. PubMed ID: 23175466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells.
    Sun WJ; Huang H; He B; Hu DH; Li PH; Yu YJ; Zhou XH; Lv Z; Zhou L; Hu TY; Yao ZC; Lu MD; Shen X; Zheng ZQ
    Biochem Pharmacol; 2017 Mar; 127():90-100. PubMed ID: 28012958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone morphogenetic protein-9 is a potent growth inhibitor of hepatocellular carcinoma and reduces the liver cancer stem cells population.
    Jung JW; Yoon SM; Kim S; Jeon YH; Yoon BH; Yang SG; Kim MK; Choe S; Kuo MM
    Oncotarget; 2016 Nov; 7(45):73754-73768. PubMed ID: 27650540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21
    Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J
    Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma.
    Khan MGM; Ghosh A; Variya B; Santharam MA; Ihsan AU; Ramanathan S; Ilangumaran S
    BMC Cancer; 2020 Aug; 20(1):774. PubMed ID: 32807134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice.
    Afaloniati H; Angelopoulou K; Giakoustidis A; Hardas A; Pseftogas A; Makedou K; Gargavanis A; Goulopoulos T; Iliadis S; Papadopoulos V; Papalois A; Mosialos G; Poutahidis T; Giakoustidis D
    Onco Targets Ther; 2020; 13():5575-5588. PubMed ID: 32606772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of insulin receptor substrates in the progression of hepatocellular carcinoma.
    Sakurai Y; Kubota N; Takamoto I; Obata A; Iwamoto M; Hayashi T; Aihara M; Kubota T; Nishihara H; Kadowaki T
    Sci Rep; 2017 Jul; 7(1):5387. PubMed ID: 28710407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway.
    Li J; Wang Q; Yang Y; Lei C; Yang F; Liang L; Chen C; Xia J; Wang K; Tang N
    J Exp Clin Cancer Res; 2019 Oct; 38(1):438. PubMed ID: 31666108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maotai ameliorates diethylnitrosamine-initiated hepatocellular carcinoma formation in mice.
    Yi X; Long L; Yang C; Lu Y; Cheng M
    PLoS One; 2014; 9(4):e93599. PubMed ID: 24690765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks.
    Helms TH; Mullins RD; Thomas-Ahner JM; Kulp SK; Campbell MJ; Lucas F; Schmidt N; LeMoine DM; Getaneh S; Xie Z; Phelps MA; Clinton SK; Coss CC
    Sci Rep; 2021 Feb; 11(1):3646. PubMed ID: 33574348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic loss of miR-122 predisposes mice to hepatobiliary cyst and hepatocellular carcinoma upon diethylnitrosamine exposure.
    Hsu SH; Wang B; Kutay H; Bid H; Shreve J; Zhang X; Costinean S; Bratasz A; Houghton P; Ghoshal K
    Am J Pathol; 2013 Dec; 183(6):1719-1730. PubMed ID: 24113455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of EGFL8 regulates migration, invasion and apoptosis of hepatocellular carcinoma through activating Notch signaling pathway.
    Wu F; Zhang FY; Tan GQ; Chen WJ; Huang B; Yan L; Zhang HL; Chen S; Jiao Y; Wang BL
    BMC Cancer; 2021 Jun; 21(1):704. PubMed ID: 34130659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent mTORC1 activation via Depdc5 deletion results in spontaneous hepatocellular carcinoma but does not exacerbate carcinogen- and high-fat diet-induced hepatic carcinogenesis in mice.
    Xu L; Yang C; Wang J; Li Z; Huang R; Ma H; Ma J; Wang Q; Xiong X
    Biochem Biophys Res Commun; 2021 Nov; 578():142-149. PubMed ID: 34562654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsa-miR-107 regulates chemosensitivity and inhibits tumor growth in hepatocellular carcinoma cells.
    Chen HA; Li CC; Lin YJ; Wang TF; Chen MC; Su YH; Yeh YL; Padma VV; Liao PH; Huang CY
    Aging (Albany NY); 2021 Apr; 13(8):12046-12057. PubMed ID: 33901009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance.
    Ma Q; Xu Q; Zhao J; Zhang W; Wang Q; Fang J; Lu Z; Liu J; Ma L
    Cancer Lett; 2021 Nov; 520():243-254. PubMed ID: 34339801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor.
    Dong S; Ma X; Wang Z; Han B; Zou H; Wu Z; Zang Y; Zhuang L
    Oncotarget; 2017 Jun; 8(25):40583-40593. PubMed ID: 28489564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
    Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
    Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.